STOCK TITAN

Emmaus Life Sciences’ Q3 net loss widens to $4.74M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Emmaus Life Sciences, Inc. (EMMA) reported third-quarter net revenue of $1.892 million, down from $3.378 million for the same period in 2025. Management attributed the decline primarily to a 44% decrease in U.S. net revenue as its licensing agreement with NeoImmuneTech became effective on May 15, 2026; lower direct sales of Endari also contributed. Operating expenses were $1.892 million, compared with $2.436 million.

Third-quarter net loss widened to $4.741 million from $2.076 million, while other expense rose to $4.4 million from $2.2 million. For the first nine months, net revenue increased to $10.192 million from $8.601 million, and operating income was $2.599 million compared with an operating loss of $0.655 million. Cash and cash equivalents were $0.971 million as of September 30, 2026. Emmaus cited doubt about its ability to continue as a going concern among its risks.

2 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

2 major · 3 points

How the balance works

Positive

  • Moderate pointNine-month net revenue increased to $10.192 million from $8.601 million.
  • Moderate pointNine-month operating income was $2.599 million, compared with a $0.655 million operating loss.

Negative

  • Major pointThird-quarter net loss widened to $4.741 million from $2.076 million.
  • Major pointEmmaus cited doubt about its ability to continue as a going concern among its risks.
  • Moderate pointThird-quarter net revenue fell to $1.892 million from $3.378 million.

Filing Explained

At September 30, 2026, Emmaus reported current liabilities of $72,886 thousand against current assets of $4,681 thousand, so liabilities classified as current exceeded assets classified as current.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Third-quarter net revenue $1.892 million Three months ended September 30, 2026; $3.378 million in the same period of 2025.
Nine-month net revenue $10.192 million Nine months ended September 30, 2026; $8.601 million in the same period of 2025.
Third-quarter operating loss $0.369 million loss Three months ended September 30, 2026; $0.695 million operating income in the same period of 2025.
Nine-month operating income $2.599 million income Nine months ended September 30, 2026; $0.655 million operating loss in the same period of 2025.
Third-quarter net loss $4.741 million loss Three months ended September 30, 2026; $2.076 million loss in the same period of 2025.
Nine-month net loss $6.737 million loss Nine months ended September 30, 2026; $5.541 million loss in the same period of 2025.
Third-quarter other expense $4.4 million Three months ended September 30, 2026; $2.2 million in the same period of 2025.
Cash and cash equivalents $0.971 million As of September 30, 2026; $2.127 million as of December 31, 2025.
conversion feature derivative financial
"Conversion feature derivative, notes payable"
going concern financial
"ability to continue as a going concern"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
weighted-average common shares financial
"based on approximately 70.2 million weighted-average common shares"
L-glutamine oral powder medical
"Endari® (L-glutamine oral powder)"
named patient or early access basis regulatory
"available on a named patient or early access basis"
Net revenue, three months $1.892 million Down from $3.378 million in the same period of 2025.
Net revenue, nine months $10.192 million Up from $8.601 million in the same period of 2025.
Operating result, three months $0.369 million loss Compared with $0.695 million operating income in the same period of 2025.
Operating result, nine months $2.599 million income Compared with $0.655 million operating loss in the same period of 2025.
Net loss, three months $4.741 million Compared with $2.076 million in the same period of 2025.
Net loss, nine months $6.737 million Compared with $5.541 million in the same period of 2025.
Other expense, three months $4.4 million Compared with $2.2 million in the same period of 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much revenue did EMMA report for the third quarter of 2026?

Net revenue was $1.892 million for the three months ended September 30, 2026, compared with $3.378 million in the same period of 2025.

What was EMMA’s net loss in the third quarter of 2026?

Net loss was $4.741 million for the three months ended September 30, 2026, compared with $2.076 million in the same period of 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0000822370 0000822370 2026-11-18 2026-11-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 18, 2026

 

Emmaus Life Sciences, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-35527   87-0419387
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (I.R.S. Employer
Identification No.)

 

21250 Hawthorne Boulevard, Suite 800, Torrance, CA   90503
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code (310) 214-0065

 

 

(Former name or former address, if changed, since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: 

 

Title of each class   Trading Symbol   Name of each exchange on which registered
None        

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 2.02 Results of Operation and Financial Condition.

 

On November 18, 2026, Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) issued a press release announcing our results of operations and financial condition as of and for the three and nine months ended September 30, 2026, a copy of which is included as Exhibit 99.1 to this Current Report and incorporated herein by reference.

 

The information included in this Item 2.02 and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits

 

See the accompanying Index to Exhibits, which is incorporated herein by reference.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 18, 2026 Emmaus Life Sciences, Inc.
     
  By: /s/ WILLIS LEE
    Name:  Willis Lee
    Title: Chairman and Chief Executive Officer

 

2

 

 

INDEX TO EXHIBITS

 

Exhibit
Number
  Description
99.1   Press release dated November 18, 2026
104   Cover Page Interactive Date File (embedded within Inline XBRL document)

 

3

 

 

Exhibit 99.1

 

 

Emmaus Life Sciences Reports Quarterly Financial Results

 

Torrance CA, November 18, 2026 - Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and nine months ended September 30, 2026.

 

Highlights

 

“Our global net revenues declined for the three months ended September 30, 2026 as compared to the same period in 2025 primarily driven by a 44% decrease in U.S. net revenues as our licensing agreement with NeoImmuneTech Inc. (NIT), became effective on May 15, 2026.” commented Willis Lee, Chairman and Chief Executive Officer of Emmaus. “The decline was partially offset by a related reduction in our operating expenses. Management believes that the conflict in the Midde East also adversely affected net revenues in the region,” he added.

 

Financial and Operating Results

 

Net Revenues. Net revenues for the three months ended September 30, 2026 were $1.9 million, compared to $3.4 million in the same period in 2025 driven by lower direct sales of Endari® following the company’s execution of the License Agreement with NIT.

 

Operating Expenses. Total operating expenses for the three months were $1.9 million compared to $2.4 million in the comparable period in 2025. The decrease was due primarily to decreased expenses attributable to the transfer of our sales force to NIT in connection with the license arrangement.

 

Income (Loss) From Operations. Loss from operations for the three months was $0.4 million compared to income from operations of $0.7 million in the same period in 2025. The changes was due to the decrease in net revenues, partially offset by lower operating expenses.

 

Other Expense. The company realized other expense of $4.4 million for the three months compared to $2.2 million in the same period in 2025. The increase was primarily due to change in fair value of conversion features derivative based upon an increase in the company’s stock price.

 

Net Loss. For the three months, the company realized a net loss of $4.7 million, or $0.07 basic loss per share based on approximately 70.2 million weighted-average common shares, compared to net loss of $2.1 million, or $0.03 basic loss per share based on approximately 63.9 million weighted-average common shares in the comparable period in 2025. The increase in net loss was attributable primarily to the decrease in net revenues and increase in other expense.

 

Liquidity and Capital Resources. At September 30, 2026, the company had cash and cash equivalents of $1.0 million, compared to $2.1 million at December 31, 2025.

 

About Emmaus Life Sciences

 

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease. Endari® (L-glutamine oral powder), indicated to reduce the acute complications of sickle cell disease in adults and children 5 years and older, is approved for marketing in the United States, Israel, Kuwait, Qatar, the United Arab Emirates, Bahrain and Oman and is available on a named patient or early access basis in France, the Netherlands, and the Kingdom of Saudi Arabia, where Emmaus’ application for marketing authorization is awaiting final action by the Saudi Food & Drug Authority. For more information, please visit www.emmausmedical.com.

 

 

 

 

About Endari® (prescription grade L-glutamine oral powder)

 

Endari®, Emmaus’ prescription grade L-glutamine oral powder, was approved by the U.S. Food and Drug Administration (FDA) in July 2017 for treating sickle cell disease in adult and pediatric patients five years of age and older.

 

Indication

 

Endari® is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

 

Important Safety Information

 

The most common adverse reactions (incidence >10 percent) in clinical studies were constipation, nausea, headache, abdominal pain, cough, pain in extremities, back pain, and chest pain.

 

Adverse reactions leading to treatment discontinuation included one case each of hypersplenism, abdominal pain, dyspepsia, burning sensation, and hot flash.

 

The safety and efficacy of Endari® in pediatric patients with sickle cell disease younger than five years of age has not been established.

 

For more information, please see full Prescribing Information of Endari® at: www.ENDARIrx.com/PI.

 

About Sickle Cell Disease

 

There are approximately 100,000 people living with sickle cell disease (SCD) in the United States and millions more globally. The sickle gene is found in every ethnic group, not just among those of African descent; and in the United States an estimated 1-in-365 African Americans and 1-in-16,300 Hispanic Americans are born with SCD.1 The genetic mutation responsible for SCD causes an individual’s red blood cells to distort into a “C” or a sickle shape, reducing their ability to transport oxygen throughout the body. These sickled red blood cells break down rapidly, become very sticky, and develop a propensity to clump together, which causes them to become stuck and cause damage within blood vessels. The result is reduced blood flow to distal organs, which leads to physical symptoms of incapacitating pain, tissue and organ damage, and early death.2

 

Forward-looking Statements

 

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time, including doubt about the company’s ability to continue as a going concern and other factors disclosed in the company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 31, 2026 and Quarterly Report on Form 10-Q filed on November 18, 2026, and actual results may differ materially. Such forward-looking statements speak only as of the date they are made, and Emmaus assumes no duty to update them, except as may be required by law.

 

Company Contact:

 

Emmaus Life Sciences, Inc.

Investor Relations

(310) 214-0065

IR@emmauslifesciences.com

 

 

1Source: Data & Statistics on Sickle Cell Disease – National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, December 2020.

2Source: Committee on Addressing Sickle Cell Disease – A Strategic Plan and Blueprint for Action -- National Academy of Sciences Press, 2020.

 

2

 

 

(Financial Tables Follow)

 

Emmaus Life Sciences, Inc.

Condensed Consolidated Statement of Operations and Comprehensive Income (Loss) (In thousands, except share and per share amounts)

 

   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
   2026   2025   2026   2025 
Revenue, Net  $1,892   $3,378   $10,192   $8,601 
Cost of Goods Sold   369    247    881    622 
Gross Profit   1,523    3,131    9,311    7,979 
Operating Expenses   1,892    2,436    6,712    8,634 
Income (loss) from Operations   (369)   695    2,599    (655)
                     
Net Loss   (4,741)   (2,076)   (6,737)   (5,541)
Comprehensive Loss   (2,476)   (3,796)   (5,045)   (3,027)
Net Loss per Share  $(0.07)  $(0.03)  $(0.10)  $(0.09)
Weighted Average Common Shares Outstanding   70,188,263    63,865,571    70,188,263    63,865,571 

 

3

 

 

Emmaus Life Sciences, Inc.

Condensed Consolidated Balance Sheets

 (In thousands)

 

   As of 
   September 30,
2026
   December 31,
2025
 
Assets        
Current Assets:        
Cash and cash equivalents  $971   $2,127 
Accounts receivable, net   1,516    2,804 
Inventories, net   1,417    1,555 
Prepaid expenses and other current assets   777    1,260 
Total Current Assets   4,681    7,746 
Property and Equipment, net   73    113 
Right of use assets   771    766 
Investment in convertible bond   10,994    12,604 
Investment in equity security   989    - 
Other Assets   227    207 
Total Assets  $17,735   $21,436 
           
Liabilities and Stockholders’ Deficit          
Current Liabilities:          
Accounts payable and accrued expenses  $25,394   $22,615 
Operating lease liabilities, current portion   401    348 
Conversion feature derivative, notes payable   3,247    - 
Notes payable, current portion   11,256    11,151 
Convertible notes payable, net of discount   17,309    17,380 
Other current liabilities   15,279    17,578 
Total Current Liabilities   72,886    69,072 
Other long-term liabilities   13,501    15,972 
Total Liabilities   86,387    85,044 
Stockholders’ Deficit   (68,652)   (63,608)
Total Liabilities & Stockholders’ Deficit  $17,735   $21,436 

 

4

 

Filing Exhibits & Attachments

4 documents

Keep reading